Treatment with anti-myeloma monoclonal antibodies within  weeks prior first dose.
A history of hypersensitivity to other humanized monoclonal antibodies.
History of severe hypersensitivity reactions to other monoclonal antibodies.
Patients who received chemotherapy (including monoclonal antibodies) or radiotherapy, administered for any condition, within  weeks prior to registration are not eligible
Significant prior infusion reaction to monoclonal antibodies that required treatment with systemic steroids
History of severe hypersensitivity reactions to other monoclonal antibodies
History of severe hypersensitivity reactions (eg, anaphylaxis) to other biologic drugs or monoclonal antibodies
History of life-threatening hypersensitivity to monoclonal antibodies or to recombinant proteins or excipients in drug formulation
History of severe hypersensitivity reactions to other monoclonal antibodies
History of severe hypersensitivity reactions to monoclonal antibodies.
Hypersensitivity to any of the inactive ingredients (histidine, sucrose, polysorbate ) or to other humanized monoclonal antibodies (mAbs)
Patients who have received anti-thymocyte globulin (ATG), Campath, or other immunosuppressive T cell monoclonal antibodies within  days
Patients who have received any cytotoxic therapy, immunotherapy, antitumor vaccines or monoclonal antibodies in the  weeks prior to the start of the study
History of grade >=  allergy to human monoclonal antibodies
Monoclonal antibodies therapy within  weeks before study entry
History of severe allergic reactions to humanized monoclonal antibodies
History of severe hypersensitivity reactions to other monoclonal antibodies
History of severe hypersensitivity reactions to other monoclonal antibodies
History of allergic reactions attributed to monoclonal antibodies (grade >= )
History of severe hypersensitivity reactions to other monoclonal antibodies
History of sensitivity or allergy to monoclonal antibodies (mAbs) or immunoglobulin G (IgG)
Allergy to murine-based monoclonal antibodies
Prior hypersensitivity to monoclonal antibodies
Monoclonal antibodies therapy within  weeks before study entry
History of grade  or higher allergy to humanized monoclonal antibodies
Exclude patients with known Kell antibodies
History of severe allergic reactions to humanized monoclonal antibodies
History of severe hypersensitivity reactions to other monoclonal Antibodies
History of grade  or above hypersensitivity reactions to other monoclonal antibodies
Patients with history of hypersensitivity to monoclonal antibodies
Patients with previous history of radiosurgery, brachytherapy, Gliadel implantation, or radiolabeled monoclonal antibodies
History of sensitivity or allergy to monoclonal antibodies or immunoglobulin G
Patients who have experienced allergic reactions to monoclonal antibodies
Documented allergy or hypersensitivity to monoclonal antibodies (bevacizumab), to Chinese hamster ovarian cells of the or to any other humanized or recombinant antibodies
No known hypersensitivity to rat monoclonal antibodies
Monoclonal antibodies therapy within  weeks before study entry
Patients receiving Anti-thymocyte globulin (ATG), Campath or other immunosuppressive T cell monoclonal antibodies within  days of treatment with Viralym-A.
Patients receiving anti-thymocyte globulin (ATG), Campath or other immunosuppressive T cell monoclonal antibodies within  days of screening for enrollment
Patients with a history of documented human anti-globulin antibodies.
Previous treatment for CLL with chemotherapy or monoclonal antibodies
History of severe hypersensitivity reactions to other monoclonal antibodies.
Patients with known hypersensitivity to any of the components of MCLA- or who have had prior hypersensitivity reactions to human or humanized monoclonal antibodies;
? weeks for monoclonal antibodies (? weeks for alemtuzumab),
Prior hypersensitivity reaction to monoclonal antibodies, other therapeutic proteins, or immunotherapy.
Concurrent immunotherapy (including monoclonal antibodies),during or within  days prior to start of study drug
Any previous treatment (chemotherapy, radiotherapy, and/or monoclonal antibodies) intended specifically to treat CLL
History of severe hypersensitivity reaction with biologics therapy (monoclonal antibodies)
Known hypersensitivity to monoclonal antibodies
History of severe hypersensitivity reactions to other monoclonal antibodies which in the opinion of the investigator may pose an increased risk of a serious infusion reaction.
-  Subjects who have received any prior chemotherapy, radiotherapy, biologic/targeted\n             anti-cancer therapy or surgery within  weeks ( weeks for monoclonal antibodies,\n             radioactive monoclonal antibodies or any radio- or toxin- immunoconjugates) before\n             the first study drug administration and have not recovered (to AEs <  Grade ) from\n             the toxic effects from any prior therapy
Prior therapy with other human or humanized monoclonal antibodies, unless HAHA tested\n             and negative
History of severe hypersensitivity reactions to other monoclonal antibodies.
History of severe hypersensitivity reactions/anaphylaxis attributed to humanized and/or chimeric monoclonal antibodies or other such proteins; hypersensitivity reactions that are clearly related to cetuximab may be permitted at the discretion of the principal investigator
Known allergy(ies) to any component of CMB, atezolizumab, or severe allergic reactions to monoclonal antibodies, fusion proteins, or CHO cell products.
For Combination Dose Finding and Combination Expansion cohorts only: history of hypersensitivity reactions/anaphylaxis attributed to humanized and/or chimeric monoclonal antibodies or other such proteins; hypersensitivity reactions that are clearly related to cetuximab may be permitted at the discretion of the lead principal investigator (PI)
History of allergy to mesothelin-directed antibodies, tubulysin, monoclonal antibodies, nivolumab or related compounds
History of allergy or hypersensitivity to human, humanized or chimeric monoclonal antibodies
Have received prior treatment with monoclonal antibodies within  weeks of first dose of Day ;
A history of allergy to human monoclonal antibodies.
Previous experimental therapy with SS moiety, murine or chimeric antibodies (human and humanized antibodies are allowed)
History of grade  or higher hypersensitivity reactions/anaphylaxis attributed to humanized and/or chimeric monoclonal antibodies or other such proteins; hypersensitivity reactions that are clearly related to cetuximab may be permitted at the discretion of the principal investigator
Subject has a known hypersensitivity to monoclonal antibodies or to agents of similar biologic composition as IMC-CS.
Subject has received treatment with any monoclonal antibodies within  weeks prior to first dose of study therapy
History of severe hypersensitivity reactions to other biologic drugs or monoclonal antibodies
Prior allergic reactions attributed to other monoclonal antibodies
Known allergy or hypersensitivity to IP formulations or to other human monoclonal antibodies
Known severe hypersensitivity reactions to monoclonal antibodies (Grade ?), any history of anaphylaxis.
History of severe hypersensitivity reactions to other monoclonal antibodies
Patients who have received any prior experimental active immunotherapy consisting of targeted monoclonal antibodies (ipilimumab) or pharmaceutical compounds are excluded.
Experienced allergic reactions to monoclonal antibodies or other therapeutic proteins.
Hypersensitivities to other monoclonal antibodies;
Monoclonal antibodies within  days
Therapeutic or experimental monoclonal antibodies in last  days prior registration.
History of severe hypersensitivity reactions or immune related adverse events to other monoclonal antibodies
Use of targeted agents (e.g., monoclonal antibodies or kinase inhibitors) will not be counted as a prior chemotherapy treatment
Prior hypersensitivity reaction to monoclonal antibodies, other therapeutic proteins, or immunotherapy.
Prior hypersensitivity to monoclonal antibodies
Patients receiving (anti-thymocyte globulin) ATG, Campath or other immunosuppressive T cell monoclonal antibodies within  days of treatment with Viralym-C
History of Grade ?  allergy to human monoclonal antibodies.
Received antithymocyte globulin (ATG), or Campath or other immunosuppressive T cell monoclonal antibodies within  days of screening for enrollment
Monoclonal antibodies: Last dose of any monoclonal antibodies must have received at least  days or  half-lives, whichever is longer, prior to the start date for protocol therapy. Please refer to table posted at www.nant.org for definition of half-lives for specific monoclonal antibodies.
History of allergic reactions to monoclonal antibodies
Patients must not have received any cytotoxic therapy, immunotherapy, antitumor vaccines or monoclonal antibodies in the  weeks prior to the start of the study
History of severe hypersensitivity to monoclonal antibodies.
History of severe hypersensitivity to monoclonal antibodies or to the chemotherapies under investigation including any ingredient used in the formulation.
History of severe hypersensitivity reactions to other monoclonal antibodies.
Have received prior treatment with monoclonal antibodies within  weeks of first dose of Day ;
Patients receiving anti-thymocyte globulin (ATG), or Campath or other immunosuppressive T cell monoclonal antibodies within  days of screening for enrollment
History of clinically significant sensitivity or allergy to monoclonal antibodies, their excipients, or intravenous gamma globulin
History of severe hypersensitivity reactions to other monoclonal antibodies, which in the opinion of the investigator may pose an increased risk of serious infusion reaction.
Known allergy or hypersensitivity to monoclonal antibodies
History of severe hypersensitivity reactions to other monoclonal antibodies.
